GlassScriptPhysician profile
Audrey Drake
NPI 1093547291
$2,079.08
in general payments reported to CMS, 2019-2025
26 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $136 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $207.55 | 2025 | Talvey, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $188.41 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $185.68 | 2024-2025 | Datroway, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $165.17 | 2025 | |
| Stemline Therapeutics INC. | $151.11 | 2025 | Orserdu |
| Tempus Ai, INC | $130.89 | 2025 | Xt Cdx |
| Abbvie INC. | $128.77 | 2025 | |
| Amgen INC. | $125.00 | 2025 | Imdelltra (Amg757) |
| Incyte Corporation | $109.81 | 2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $80.27 | 2024-2025 | Rybrevant, Balversa, Erleada |
| Tersera Therapeutics LLC | $72.78 | 2025 | Zoladex, Xermelo |
| Astellas Pharma US INC | $71.26 | 2025 | Vyloy, Padcev |
| Merck Sharp & Dohme LLC | $69.40 | 2024-2025 | Keytruda, Keytruda Qlex |
| Aveo Pharmaceuticals, INC. | $67.41 | 2025 | |
| Pfizer INC. | $46.54 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45.15 | 2024-2025 | |
| Daiichi Sankyo INC. | $39.73 | 2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $29.04 | 2025 | Ojjaara |
| Exelixis INC. | $27.19 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $26.62 | 2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $22.62 | 2025 | Romvimza, Qinlock |
| Genentech USA, INC. | $21.27 | 2025 | Venclexta |
| Kyowa Kirin, INC. | $21.09 | 2025 | |
| Gilead Sciences, INC. | $16.55 | 2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $15.97 | 2024 | |
| Geron Corporation | $13.80 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.